Abortive headache therapy in the office with intravenous dihydroergotamine plus prochlorperazine.

Abstract

Over two years, 92 patients were treated in the office for 146 severe headache episodes. Headaches were aborted using four different intravenous regimens containing 0.5 or 1 mg. of dihydroergotamine and 3.5, 5, or 10 mg. of prochlorperazine. The speed and rate of response were directly proportional to the prochlorperazine dose used. High prochlorperazine doses (10 mg.) aborted the most headaches (95%) in the shortest time, but caused more sedation and akathesia. Low doses (3.5 mg.) aborted less headaches (89%) and responses were delayed; but, on the other hand, sedation was minimal and akathesia mild and uncommon. Dihydroergotamine given alone caused intolerable side effects; but, when it was given with prochlorperazine, efficacy was enhanced and side effects were greatly reduced. Aborting headaches in the office can be reliably achieved with minimal side effects by administering an intravenous mixture containing 1 mg. of dihydroergotamine and 3.5 mg. of prochlorperazine.

• Authors: H A Saadah
• Journal: Headache (Headache) Vol. 32 Issue 3 Pg. 143-6 (Mar 1992) ISSN: 0017-8748 [Print] United States
• PMID: 1563946 (Publication Type: Journal Article)

Chemical References

• Dihydroergotamine
• Prochlorperazine

Topics

• Adolescent
• Adult
• Aged
• Dihydroergotamine (administration & dosage, adverse effects)
• Drug Therapy, Combination
• Female
• Headache (drug therapy)
• Humans
• Injections, Intravenous
• Male
• Middle Aged
• Office Visits
• Prochlorperazine (administration & dosage, adverse effects)
• Time Factors